KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature

被引：0
作者：
Zafrakas, M. [1 ]
Theodoridis, T. D. [1 ]
Zepiridis, L. [1 ]
Venizelos, I. D. [2 ]
Agorastos, T. [1 ]
Bontis, J. [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol 1, Papageorgiou Gen Hosp, Periferiaki Odos Thessalonikis N Efkarpia, Thessaloniki 56403, Greece
[2] Hippokrateion Hosp, Dept Pathol, Thessaloniki, Greece
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2008年 / 29卷 / 03期
关键词：
uterine sarcoma; KIT; imatinib mesylate;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: The aim of the present study was to investigate the possibility of treating uterine sarcomas with imatinib mesylate. Imatinib mesylate, a selective tyrosine kinase inhibitor, is very efficient against mesenchymal tumors of the gastrointestinal tract, known as GISTs. Imatinib mesylate acts against a tyrosine kinase encoded by the KIT gene in GISTs, and is more effective in tumors expressing this protein. Methods: Expression of KIT was analyzed immunohistochemically (n = 12) in formalin-fixed paraffin-embedded primary uterine sarcomas. Results: Using a semi-quantitative immunohistochemical score we found that KIT expression was very weak in the majority of tumors, while none of the uterine sarcomas tested showed strong expression. Overall, published studies addressing this issue in small series of uterine sarcomas yielded similar results. Conclusion: Current data suggest that it is unlikely that imatinib mesylate could be used effectively as a single agent in patients with uterine sarcomas.
引用
收藏
页码：264 / 266
页数：3
相关论文
共 23 条
[1]   The role of surgery and treatment trends in uterine sarcoma [J].
Benoit, L ;
Arnould, L ;
Cheynel, N ;
Goui, S ;
Collin, F ;
Fraisse, J ;
Cuisenier, J .
EJSO, 2005, 31 (04) :434-442
[2]   Treatment of gastrointestinal stromal tumors with imatinib mesylate: A major breakthrough in the understanding of tumor-specific molecular characteristics [J].
de Mestier, P ;
des Guetz, G .
WORLD JOURNAL OF SURGERY, 2005, 29 (03) :357-361
[3]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[4]  
FORNEY JP, 1981, CONTEMP OBSTET GYNEC, V18, P47
[5]   Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].
Hirota, S ;
Isozaki, K ;
Moriyama, Y ;
Hashimoto, K ;
Nishida, T ;
Ishiguro, S ;
Kawano, K ;
Hanada, M ;
Kurata, A ;
Takeda, M ;
Tunio, GM ;
Matsuzawa, Y ;
Kanakura, Y ;
Shinomura, Y ;
Kitamura, Y .
SCIENCE, 1998, 279 (5350) :577-580
[6]   Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [J].
Joensuu, H ;
Roberts, PJ ;
Sarlomo-Rikala, M ;
Andersson, LC ;
Tervahartiala, P ;
Tuveson, D ;
Silberman, SL ;
Capdeville, R ;
Dimitrijevic, S ;
Druker, B ;
Demetri, GD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1052-1056
[7]   Systemic therapy for advanced uterine sarcoma: A systematic review of the literature [J].
Kanjeekal, S ;
Chambers, A ;
Fung, MFK ;
Verma, S .
GYNECOLOGIC ONCOLOGY, 2005, 97 (02) :624-637
[8]   Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary [J].
Klein, WM ;
Kurman, RJ .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (02) :181-184
[9]  
Leath CA, 2004, J REPROD MED, V49, P71
[10]   A comparison between different postoperative treatment modalities of uterine carcinosarcoma [J].
Menczer, J ;
Levy, T ;
Piura, B ;
Chetrit, A ;
Altaras, M ;
Meirovitz, M ;
Glezerman, M ;
Fishman, A .
GYNECOLOGIC ONCOLOGY, 2005, 97 (01) :166-170
123